Portuguese researchers analyzing 922 individuals identified two key PON1 gene variants (rs2057681 and rs854572) that create specific haplotype combinations predicting dysglycemia and liver fibrosis risk in adults over 55. The variants modulate paraoxonase enzyme activity, which protects against oxidative stress damage. Surprisingly, enzyme activity levels didn't directly correlate with disease risk—instead, specific genetic combinations themselves determined susceptibility regardless of actual enzyme function. This challenges the assumption that higher antioxidant enzyme activity always provides better metabolic protection. The findings suggest PON1 genetic testing could identify individuals at elevated risk for metabolic dysfunction-associated liver disease and diabetes before symptoms appear, enabling targeted preventive interventions. However, this preprint study from a single Portuguese cohort requires peer review and validation across diverse populations. The discovery that genetic context matters more than enzyme activity represents a nuanced advance in understanding metabolic disease genetics, though it builds incrementally on existing PON1 research rather than providing paradigm-shifting insights. Clinical translation would require larger studies confirming these genetic risk patterns predict actual disease outcomes.